The standards applied to the patentability of inventions in oncology and biotechnology have been dramatically altered in the last few years. Among the significant changes is the U.S. Supreme Court’s 2013 ruling that the isolated human BRCA1 and BRCA2 genes used by Myriad Genetics to test for breast cancer were “unpatentable subject matter.”
Oncology and biotech companies will need to make major changes to their business, research, and patent strategies to account for these developments.
During this seminar, held in conjunction with the Southeast Investor & Venture Philanthropy Oncology Summit 2015, attendees will learn about recent changes in patent law relating to patent-eligible subject matter—as well as the strength of disclosure required—and learn how to use these changes as tools rather than hurdles.
Please join our workshop for in-depth discussions on the following topics:
- Changes in the patentability of oncology and biotech inventions
- Optimal timing to file a patent application
- Recognizing events that trigger an immediate need to file
- Elements of a strong patent disclosure
- Balancing speed versus strength in first-to-file decisions
There is no charge to attend the program. Register by Friday, May 1, 2015. Space is limited, so please register early.
Mark J. Feldstein, Ph.D., JD Ryan P. O'Quinn, Ph.D., JD
Finnegan With remarks by: Anil K. Goyal, Ph.D.,
Heat Biologics, Inc.
Matt D. Medlin, Ph.D., RAC, CCRP
Cato Research, Ltd.
Tuesday, May 5, 2015
North Carolina Biotechnology Center
15 T.W. Alexander Drive
Research Triangle Park, NC 27709
4:30 - 6:00 p.m. Reception (with Oncology Summit attendees)
6:00 - 7:30 p.m. Program
7:30 - 8:00 p.m. Dessert and Networking Reception
In Partnership with the North Carolina Biotechnology Center